Atrasentan

Overview

Atrasentan is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL9194).

API suppliers (1)

Suppliers of Atrasentan backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Catalent Pharma Solutions, Inc.United States

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Atrasentan expires 25 Mar 2043 and exclusivity 1 Apr 2030. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid

Canonical SMILES

CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4

InChIKey

MOTJMGVDPWRKOC-QPVYNBJUSA-N